Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 22Active not recruiting 9Completed 4Terminated 3Suspended 2Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Breast Neoplasms 10Neoplasms 9Leukemia, Myeloid, Acute 9Glioblastoma 9Colorectal Neoplasms 8Neoplasm Metastasis 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Hematologic Neoplasms 5Ovarian Neoplasms 4Glioma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Sarcoma 3Melanoma 3Head and Neck Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neoplasm, Residual 2

Interventions

Azacitidine 2duvelisib 1Vincristine 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Lymphoma, T-Cell × 90 days × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡